HOOKIPA Pharma IncNASDAQ:HOOK
- LAST PRICE3.7800
- TODAY'S CHANGE (%)0.0200 (0.5319%)
- Bid / Lots3.7700/ 3
- Ask / Lots3.8400/ 1
- Open / Previous Close3.7900 / 3.7600
- Day Range
- 52 Week Range
- Volume617
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HOOK |
|---|---|---|
| 09:32 ET | 156 | 3.79 |
| 09:33 ET | 400 | 3.78 |
Oct 31, 2024
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024, from 9:17AM ET on Thursday Oct 31, 2024 by Dow Jones
9:17AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 30, 2024
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer, from 7:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
HOOKIPA Pharma Inc | 45.3M | -0.7x | --- |
Prenetics Global Ltd | 53.3M | -1.2x | --- |
Celularity Inc | 34.1M | -0.2x | --- |
Aadi Bioscience Inc | 48.2M | -0.8x | --- |
Carisma Therapeutics Inc | 43.6M | -0.6x | --- |
ImmuCell Corp | 28.1M | -7.0x | --- |
Company Information
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Contact Information
- Headquarters
- 350 Fifth Avenue, 72Nd Floor, Suite 7240NEW YORK, NY, United States 10118
- Phone
- ---
- Fax
- 302-655-5049
Executives
- Non-Executive Independent Chairman of the Board
- Julie O'Neill
- Chief Executive Officer, Director
- Malte Peters
- Chief Financial Officer, Executive Vice President, Director
- Terry Coelho
- Chief Operations Officer
- Roman Necina
- Chief Scientific Officer
- Klaus Orlinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $45.3M |
|---|---|
Revenue (TTM) | $52.2M |
Shares Outstanding | 12.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | $-5.28 |
Book Value | $7.45 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 0.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -124.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
